Secondary Logo

Journal Logo

Interleukin-22: Implications for Liver Ischemia-Reperfusion Injury

Chestovich, Paul J.1; Uchida, Yoichiro1,2; Chang, William1; Ajalat, Mark1; Lassman, Charles1; Sabat, Robert3; Busuttil, Ronald W.1; Kupiec-Weglinski, Jerzy W.1,4

doi: 10.1097/TP.0b013e3182449136
Basic and Experimental Research
Free

Background. Ischemia-reperfusion injury (IRI) is common in general surgery and organ transplantation, and in the case of liver, it triggers proinflammatory innate immune cascade and hepatic necrosis, leading to increased incidence of early and late organ rejection. Interleukin (IL)-22, an inducible cytokine of T-cell origin and a member of the IL-10 superfamily, acts on target tissues through IL-22 receptor (IL-22R1).

Methods. Partial hepatic warm ischemia was induced in C57Bl/6 wild-type (WT) and type 1 interferon receptor-deficient (KO) mice for 90 min followed by 6 to 24 hr of reperfusion. WT mice were treated at 30 min before the ischemia insult with recombinant IL-22 or anti-IL-22 neutralizing antibody; phosphate-buffered saline and IgG served as respective controls.

Results. IL-22 was detected at 24 hr but not 6 hr of liver IRI. The expression of IL-22R1 was increased by 6 hr of reperfusion in WT but not type 1 interferon receptor KO mice that were protected from IRI. Treatment of WT mice with recombinant IL-22 decreased serum aspartate aminotransferase levels, ameliorated cardinal histological features of IR damage (Suzuki's score) and diminished leukocyte sequestration, along with the expression of IL-22R1 and pro-inflammatory cytokines. IL-22 antibody did not appreciably affect IRI but increased IL-22R1 transcription in the liver. Administration of IL-22 protein exerted hepatoprotection by STAT3 activation.

Conclusions. This is the first report investigating immune modulation by T-cell-derived IL-22 in liver injury caused by warm ischemia and reperfusion. Treatment with IL-22 protein may represent a novel therapeutic strategy to prevent liver IRI in transplant recipients.

1Division of Liver and Pancreas Transplantation, Department of Surgery, Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

2Currently, Department of Hepatobiliary, Pancreas and Transplant Surgery Kyoto University Hospital, Kyoto, Japan; formerly, Division of Liver and Pancreas Transplantation, Department of Surgery, Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.

3Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.

This work was supported by the NIH grants DK 062357-07, DK 062357-06S1, DK 083408-01A1, The Diann Kim Foundation, and the Dumont Research Foundation.

The authors declare no conflicts of interest.

Presented, in part, at the American Transplant Congress, May 5, 2010, San Diego, CA.

Address correspondence to: Jerzy W. Kupiec-Weglinski, M.D., Ph.D., Dumont-UCLA Transplant Center 77-120 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095. E-mail: jkupiec@mednet.ucla.edu

P.J.C. participated in research design, performance of the research, data analysis, and writing of the manuscript; Y.U. performed microsurgery procedures and participated in analysis; W.C. and M.A. performed immunohistological stainings; C.L. provided immunohistological expertise; R.S. was the discussant and advisor; R.W.B. participated in discussion and provided partial funding; and J.W.K.W. was the overall advisor, facilitated the final manuscript version, and sponsored the project.

Received 22 September 2011. Revision requested 6 October 2011.

Accepted 30 November 2011.

Ischemia-reperfusion injury (IRI) in the liver is a major complication of hemorrhagic shock, liver resection, and transplantation (1, 2). IRI resulting from donor organ retrieval, cold storage, and warm ischemia during the surgery often leads to primary organ nonfunction and increased incidence of rejection episodes requiring retransplantation. Mechanistically, liver IRI represents a continuum of local immune processes that include endothelial activation, increased expression of adhesion molecules, Kupffer cell/neutrophil activation, and cytokine release, followed by ultimate endothelial cell and hepatocyte death (3, 4). We have characterized toll-like receptor 4-dependent innate immune mechanisms that initiate liver IRI cascade (5, 6). However, activated Kupffer cells release superoxide radicals, tumor necrosis factor (TNF)-α and interleukin (IL)-1, which promote nuclear factor-kappa B activation, resulting in the recruitment of activated T cells (7). Indeed, we and others have shown that by expressing costimulation molecules and releasing proinflammatory cytokines, activated Th cells are crucial in the pathophysiology of liver IRI (79).

IL-22, an inducible cytokine of the IL-10 superfamily, is produced by selected T cells (Th17, Th22, γ/δ, and natural killer T cells) (10). Its biological activity, unlike other cytokines, does not serve the communication between immune cells, but signals directly to the tissue. Its tissue action is through a heterodimer IL-10R2/IL-22R1 complex. In contrast to IL-10R2, which is ubiquitously expressed and largely dispensable, the expression of IL-22R1 is restricted to epithelial cells including hepatocytes, and has not been detected in cells of the hematopoietic lineage.

By increasing tissue immunity in barrier organs such as skin, lungs, and the gastrointestinal tract, IL-22 has been associated with a number of human diseases and to contribute to the pathogenesis of psoriasis, rheumatoid arthritis, and Crohn's disease (1013). However, parallel studies in murine models of mucosal defense against pulmonary bacterial infection, inflammatory bowel disease, or acute/chronic liver failure indicate that IL-22 may exert immunoregulatory pathologic versus protective functions, depending on the context in which it is expressed (1419). Moreover, HepG2/Hep3B cells transfected with IL-22 grew more rapidly and were resistant to serum starvation compared with cells devoid of IL-22, suggesting that IL-22 may serve as hepatocyte survival factor (16). Thus, advancing our appreciation of the IL-22-IL-22R1 biology may yield novel therapeutic targets in multiple human diseases.

Although IL-22 is thought to orchestrate innate-adaptive immune cross-regulation and may facilitate protection, its function in liver IRI pathology remains to be elucidated. Here, we report on the role of IL-22 in the mechanism of hepatocellular damage versus hepatoprotection in a well-defined mouse model of in situ liver warm ischemia followed by reperfusion.

Back to Top | Article Outline

RESULTS

Distinct kinetics of IR- versus ConA-induced IL-22 expression in the liver. Mouse livers subjected to 90 min of partial warm ischemia were analyzed for IL-22 expression by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) at 6 and 24 hr of reperfusion (Fig. 1a). Unlike at 6 hr, significantly increased mRNA levels coding for IL-22 were detected at 24 hr (P<0.05). Livers from ConA-induced T-cell hepatitis model served as positive controls. In agreement with published data (16, 17), markedly increased IL-22 mRNA levels at 6 hr (P<0.005) returned to baseline by 24 hr after ConA challenge (Fig. 1a).

FIGURE 1

FIGURE 1

IL-22R1 transcription correlates with the hepatocellular damage. We detected an increase in IL-22R1 expression by qRT-PCR in both ConA (P<0.005) and IRI (P<0.05) models at 6 hr, with a return to baseline after 24 hr (Fig. 1b). In contrast, IL-10R2 expression was comparable between sham, ConA, and IRI models throughout (Fig. 1c).

Separate cohorts of wild-type (WT) and type 1 interferon receptor (IFNAR)-deficient (KO) mice were subjected to 90 min of warm ischemia. Consistent with our previous findings (18), disruption of IFNAR signaling significantly reduced serum aspartate aminotransferase (sAST) levels (Fig. 2a), diminished the Suzuki score of IR-liver damage (Fig. 2b) and ameliorated local inflammation response, measured by hepatic IL-1β, TNF-α, and IL-6 levels (Fig. 2c) by 6 hr of reperfusion, when compared with WT controls. No changes in IL-22 or IL-10R2 expression were noted by qPCR between the groups (Fig. 2d). In contrast, IL-22R1 levels were selectively and significantly (P<0.05) decreased in IFNAR KO mice.

FIGURE 2

FIGURE 2

Exogenous recombinant IL-22 (rIL-22) lessens IR-triggered hepatocellular damage. We next investigated the ability of exogenous rIL-22 to affect liver IRI. Indeed, pretreatment with rIL-22 at 30 min before ischemic insult significantly decreased sAST levels at 6 hr of reperfusion (the peak of liver damage in this model) when compared with phosphate-buffered saline (PBS) controls (Fig. 3a, P<0.05). Consistent with systemic liver enzyme levels data, the Suzuki scoring of hepatocyte congestion, vacuolization, and early zonal necrosis were selectively decreased in rIL-22 treatment group compared with the PBS group (3.2±0.4 vs. 4.4±0.3; Fig. 3b,c, P<0.05).

FIGURE 3

FIGURE 3

Exogenous rIL-22 decreases IR-liver inflammatory response and IL-22R1 transcription. By 6 hr of reperfusion, we detected decreased expression of IL-1β (P<0.05) and TNF-α (P<0.005) in rIL-22, but not PBS-treated livers (Fig. 3d). IL-22 and IL-10R2 levels remained comparable in sham, PBS, and rIL-22 treatment groups (Fig. 3e). However, unlike in controls, infusion of rIL-22 significantly (P<0.05) decreased IL-22R1 mRNA expression levels.

IL-22 neutralization in WT mice does not alter liver IRI but increases IL-22R1 transcription. We then analyzed whether neutralization of native IL-22 levels at 30 min before the ischemia insult may affect liver IRI cascade. As shown in Figure 4(a), by 6 hr of reperfusion sAST levels were similar in IgG and anti-IL-22 antibody (Ab) groups. In addition, liver IRI Suzuki scores were comparable between both groups, exhibiting moderate to severe damage, with congestion and early necrotic changes (Fig. 4b,c). Similarly, anti-IL-22 treatment did not affect the expression of IL-1β, TNF-α, and IL-6 (Fig. 4d). Interestingly, the expression of mRNA coding for IL-22R1 but not for IL-10R2 increased selectively in animals conditioned with anti-IL-22 Ab when compared with those given control IgG (Fig. 4e).

FIGURE 4

FIGURE 4

Exogenous rIL-22, but not anti-IL-22 Ab, reduces neutrophil, macrophage, and T-cell sequestration in IR-livers. We performed immunohistochemical staining for cells that migrated to IR livers at 6 hr. As shown in Figure 5(a), rIL-22 treatment significantly decreased the number of hepatic neutrophils (Ly-6G), when compared with controls (19.6±3.3 vs. 40.3±5.1; P<0.05). Similarly, liver-accumulating macrophages (CD11b+) were significantly reduced after infusion of rIL-22 when compared with PBS controls (Fig. 5b; 22.9±4.4 vs. 46.7±9.2; P<0.05). Although relatively few CD3+ T cells could be found in liver samples, their numbers decreased further after treatment with rIL-22, when compared with PBS controls (Fig. 5c; 2.6±0.34 vs. 3.6±0.32; P<0.05). No differences were found in liver accumulation of neutrophils (Fig. 5a), macrophages (Fig. 5b) and T cells (Fig. 5c) between anti-IL-22 Ab and control IgG treatment groups.

FIGURE 5

FIGURE 5

IL-22 functions in liver IRI by STAT3 phosphorylation. We studied p-STAT-3 expression in our liver IRI experimental system by Western blots. As shown in Figure 5(d), significantly elevated (P<0.05) levels of p-STAT3 were found in rIL-22 (0.29±0.094 absorbance unit [AU]) when compared with PBS (0.069±0.03 AU) group. Conversely, significantly decreased (P<0.05) STAT3 phosphorylation was detected in anti-IL-22 (0.026±0.009 AU) when compared with control IgG-treated (0.16±0.051 AU) recipients.

Back to Top | Article Outline

DISCUSSION

IL-22 is a cytokine with unique properties and therapeutic potential (10, 1921). Although classified as a T-cell-derived IL, IL-22 does not communicate between leukocytes, but instead it exerts action on target tissues that express functional IL-22R1. Our present findings complement data from other liver models of T-cell hepatitis (1517), lipogenesis/steatosis (22), chronic alcohol injury (23), and intestinal ulcerative colitis (24), by documenting the beneficial effects of exogenous rIL-22 in a model of partial hepatic warm ischemia followed by reperfusion. We have used a mouse model of ischemia and reperfusion, which is a well-established, highly reproducible model of acute local liver injury, and is ideal for furthering the study of IL-22 signaling.

Liver expression of IL-22 increases sharply in T-cell hepatitis at 6 hr (16), so by using this as a positive control, we first demonstrated that its levels remained low and within sham-controls by 6 hr of reperfusion, a period of the maximal hepatocellular damage in our liver model of 90 min warm ischemia (5, 8). The low expression of IL-22 at this early time point of reperfusion is not surprising considering warm hepatic IRI is an innate-dominated immune response (5). Indeed, we consistently detect less than 5×106 of mononuclear cells in mouse livers subjected to warm IRI (vs. <0.5×106 in sham-control livers). Low IL-22 levels in our model were confirmed after its neutralization, which did not yield any significant differences in liver inflammation, histological damage, or leukocyte sequestration. In contrast, IL-22 neutralization (16) or IL-22 gene ablation (17) worsened liver damage in more stringent and fulminant Con A-induced T-cell-mediated hepatitis models.

IL-22 receptor consists of tissue-specific IL-22R1 and broadly expressed IL-10R2 (10). Tissues that lack IL-22R1 will not be a target for IL-22 under currently known molecular pathways. Unlike in ConA and IR liver injury models, we found low IL-22R1 expression in IFNAR KO mice that are resistant against hepatic IRI. Increased IL-22R1 was reported in mouse models of ConA hepatitis (16), Crohn's disease (24, 25), and in human psoriatic skin lesions (26). These findings imply local IL-22R1 expression increases in stressed inflamed tissues. Future use of liver-specific IL-22 transgenic mice (20) and mice that lack IL-22R1 selectively on their hepatocytes (Dr. R. Sabat, personal communication, 2011) will be critical to address the true importance of IL-22R1–IL-22 signaling in the liver.

Consistent with the pathogenic role of IL-22 neutralization to exacerbate hepatocellular damage (16, 17), livers in IL-22 transgenic mice were found to regenerate faster after partial hepatectomy, in association with increased expression of metallothionein 1 and 2, known to play an important role in liver regeneration (27). Hence, IL-22 overexpression is likely crucial in recovery after the liver damage. In our studies, ischemic livers subjected to 24 hr of reperfusion demonstrated increased IL-22 expression, accompanied by more defined areas of necrosis and hepatocyte recovery. We believe that IL-22 may be essential in liver regeneration and tissue repair after IR insult, and pretreatment with rIL-22 likely accelerates this process.

In parallel with increased IL-22R1 levels, IR-livers in WT mice expressed increased proinflammatory cytokine levels and exhibited significant histological damage when compared with IFNAR KO mice. As cytokine assays were performed on serum samples, the results indicate that lipopolysaccharide did not contaminate the experimental preparations. Given the ability of IL-22 to promote hepatocyte survival, and augmented IL-22R1 expression in inflamed stressed tissue (20), we hypothesized that IL-22 may improve hepatic IRI pathology. Indeed, pretreatment with rIL-22 significantly decreased sAST levels, reduced hepatic sequestration of leukocytes, and expression of pro-inflammatory cytokines. Histological examination revealed improved tissue architecture after rIL-22, as evidenced by the Suzuki score, although some ischemic damage was still evident.

Little is known about the expression and upstream signaling of IL-22R1, although the downstream phosphorylation of STAT3 has been well described (16, 20). Indeed, deletion of STAT3 in hepatocytes abolished IL-22-mediated protection in alcoholic liver injury (16). Our data confirm an increase in STAT3 phosphorylation in livers after rIL-22 pretreatment, and significantly decreased STAT3 activation after IL-22 neutralization. Our data also show that IL-22R1 transcription increased sharply in settings of stress-induced liver inflammation. IL-22R1 expression decreased after treatment with rIL-22 and increased after IL-22 neutralization. However, whether this is due to diminished local inflammation or direct negative IL-22 feedback mechanism remains to be determined. Recently described IL-22 transgenic/liver-specific STAT3 KO bigenic mouse in which IL-22 gene is overexpressed although STAT3 gene is deleted in hepatocytes (23) would be invaluable tool to address some of these key questions.

Although IL-22 can decrease some injury from IR by modulating the inflammation response, it is not a preventative hepatoprotective mechanism in WT recipients, unlike near-complete injury prevention seen in mice deficient in type I IFN signaling (18). The ischemic injury, characterized by local metabolic disturbances of glycogen consumption, lack of oxygen supply, and ATP depletion is followed by a brisk production of proinflammatory cytokine programs on reperfusion (4). During early ischemic insult by 6 hr of reperfusion, hepatocytes undergo a spectrum of damages, ranging from mild to severe, accompanied by increased expression of IL-22R1 and proinflammatory cytokine programs. As the reperfusion continues, hepatocytes recover or progress to irreversible necrosis. After treatment with rIL-22, the damaged hepatocytes express IL-22R1, which is bound by rIL-22 to form the IL-22 receptor complex, thereby stimulating downstream signaling pathways that promote hepatocyte regeneration/survival. Moderately damaged hepatocytes, which previously would have continued to necrosis without IL-22, are now able to recover. Mildly damaged hepatocytes recover with or without therapy, whereas those severely damaged proceed to necrosis regardless of the treatment.

In conclusion, this is the first report that documents benefits of T-cell-derived IL-22 immune modulation in stress-induced liver damage caused by warm ischemia and reperfusion. Low endogenous IL-22 levels at 6 hr of IRI increase by 24 hr of reperfusion when liver recovers from the ischemic insult. Hepatocyte IL-22R1 transcription during IR-liver inflammation correlates with the extent of hepatocellular damage. Exogenous IL-22 protein decreased local inflammation, diminished leukocyte sequestration, and IRI severity, whereas IL-22 neutralization did not appreciably alter IR pathology. Thus, IL-22 treatment should be considered as a novel therapeutic option to prevent liver IRI in transplant recipients.

Back to Top | Article Outline

MATERIALS AND METHODS

Animals

Male WT (Harlan Laboratories, Indianapolis, IN) and type-I IFN receptor deficient (IFNAR KO; Dr. G. Cheng, UCLA) mice were used (C57BL/6; age 8–12 weeks). Animals, housed in the UCLA animal facility under specific pathogen-free conditions, received humane care according to the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences (National Institute of Health publication 86-23 revised 1985).

Back to Top | Article Outline

Warm Hepatic IRI Model

We used a warm hepatic IRI model, as described (5, 8). In brief, mice were injected with heparin (100 μg/kg intravenously) and an atraumatic clamp was placed to interrupt arterial and portal venous blood supply to the cephalad liver lobes. After 90 min, the clamp was removed and the liver reperfused. Sham controls underwent the same procedure, but without vascular occlusion. Mice were killed at 6 and 24 hr of reperfusion, at which time peripheral serum samples were obtained, and liver lobes subjected to ischemia were collected for RT-PCR, histologic, and immunohistochemical analyses. To study the role of IL-22, animals were intravenously treated at 30 min before the ischemia insult with rIL-22 (5 μg in 200 μL PBS; BioLegends, San Diego, CA) or goat anti-mouse IL-22 Ab (AF582; 50 μg in 200 μL PBS; R&D Systems, Minneapolis, MN). Controls received PBS (200 μL) or normal goat IgG (AB-1080C, 50 μg in 200 μL PBS; R&D Systems), respectively. All treated mice were killed at 6 hr of reperfusion; serum and tissue samples were collected. The AST levels were screened in serum samples by an autoanalyzer (ANTECH Diagnostics, Los Angeles, CA).

Back to Top | Article Outline

ConA-Induced Hepatitis Model

Mice were injected with ConA (15 μg/g; Sigma, St. Louis, MO) or PBS intravenously, as described (16, 17) and killed at 6 or 24 hr for sera/liver sample analyses.

Back to Top | Article Outline

Liver Histology/Immunohistochemistry

Liver specimens were fixed in 10% buffered formalin and embedded in paraffin. Liver sections (4 μm) were stained with hematoxylin-eosin, and analyzed blindly using Suzuki's histological criteria of liver damage (28).

For immunohistochemistry, snap-frozen liver cryostat sections (4 μm) were fixed in acetone. Endogenous peroxidase activity was inhibited by peroxidase blocking agent (Dako, Carpinteria, CA), and sections were blocked with 10% normal goat serum. Primary Abs (BD Biosciences) against CD11b (M1/70), Ly-6G (1A8), and CD3 (17A2) were diluted to 1/50, 1/200, and 1/50 in 3% normal goat serum, respectively. Secondary goat anti-rat IgG (Vector Laboratories, Burlingame, CA) was diluted at 1/200. Sections were incubated with immunoperoxidase (ABC kit, Vector), washed, and developed with a 3,3′-diaminobenzidine kit (Vector). Negative controls were prepared by omission of the primary Ab. Sections were evaluated by counting positive-staining cells (hematoxylin-eosin) in portal triads of five high-power fields per slide, and results are expressed as average number of positive cells/high-power field.

Back to Top | Article Outline

Quantitative RT-PCR

RNA was extracted from snap-frozen liver tissue samples using the TRIzol technique (Invitrogen, Carlsbad, CA) (6, 7). Five micrograms of RNA was reverse-transcribed into cDNA using oligo-dT primers with Superscript III First-Strand Synthesis System (Invitrogen). Quantitative PCR was performed using the DNA Engine with Chromo 4 Detector (MJ Research, Waltham, MA). In a final volume of 20 μL, the following were added: 1X SuperMix (Platinum SYBR Green qPCR SuperMix-UDG with ROX, Invitrogen), complementary cDNA, and 0.2 μM of each primer. Amplification conditions were as follows: 50°C (2 min), 95°C (5 min) followed by 45 cycles of 95°C (15 sec) and 60°C (30 sec). Primers were used to detect IL-1β, TNF-α, IL-6, IL-22, IL-22R1, and IL-10R2. Replication levels were calculated using a 1:5 standard curve dilution, and hypoxanthine-guanine-phosphoribosyltransferase replication was used as a standard housekeeping gene.

Back to Top | Article Outline

Western Blots

Protein was extracted from liver tissue with protein lysis buffer (50 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid [HEPES], 10 mM MgCl2, 1 mM ethylenediaminetetraacetic acid [EDTA], 1 mM ethyleneglycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid [EGTA], 0.08 mM sodium molybdate, 2 mM sodium pyrophosphate, 0.01% Triton X100) with Protease Inhibitor cocktail (Sigma) and PhosSTOP phosphatase inhibitor (Roche Diagnostics, Indianapolis, IN). Proteins were prepared in Loading Buffer (EC-886, National Diagnostics, Atlanta, GA), subjected to 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis in TRIS/Glycing/ sodium dodecyl sulfate (SDS) buffer (Bio-Rad, Hercules, CA) and transferred to polyvinylidene fluoride membrane in TRIS/Glycine buffer. Primary Ab blotting was performed for p-STAT3, STAT3, and β-actin (Cell Signaling, Beverly, MA). Secondary Ab included anti-rabbit HRP- and anti-rat HRP-linked IgG. Detection was performed with the Super Signal West Pico chemiluminescent substrate system (Thermo Fisher Scientific, Rockford, IL). The relative protein quantities were determined by densitometer, and expressed in AU.

Back to Top | Article Outline

Statistical Analysis

All values are expressed as mean±SEM. Data were analyzed with an unpaired two-sided Student's t test. P less than 0.05 was considered statistically significant. Unless stated otherwise, all statistical comparisons were between experimental groups (WT vs. IFNAR KO, PBS vs. rIL-22, and IgG vs. anti-IL-22 Ab). Results from sham experiments are displayed for reference.

Back to Top | Article Outline

REFERENCES

1. Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: A brief review. Mol Med 2008; 14: 337.
2. Land W, Messmer K. The impact of ischemia/reperfusion injury on specific and non-specific early and late chronic events after organ transplantation. Transplant Rev 1996; 10: 108.
3. Fondevila C, Busuttil RW, Kupiec-Weglinski JW. Hepatic ischemia/reperfusion injury—A fresh look. Exp Mol Pathol 2003; 74: 86.
4. Zhai Y, Busuttil RW, Kupiec-Weglinski JW. Liver ischemia and reperfusion injury: New insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am J Transplant 2011; 11: 1563.
5. Zhai Y, Shen XD, O'Connell R, et al.. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173: 7115.
6. Shen XD, Ke B, Zhai Y, et al.. Toll-like receptor and heme-oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant 2005; 5: 1793.
7. Caldwell CC, Tschoep J, Lentsch AB. Lymphocyte function during hepatic ischemia/reperfusion injury. J Leukoc Biol 2007; 82: 457.
8. Shen X, Wang Y, Gao F, et al.. CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury. Hepatology 2009; 50: 1537.
9. Kuboki S, Sakai N, Tschop J, et al.. Distinct contributions of CD4+ T cell subsets in hepatic ischemia/reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2009; 296: G105.
10. Wolk K, Witte E, Witte K, et al.. Biology of interleukin-22. Semin Immunopathol 2010; 32: 17.
11. Ma HL, Liang S, Li J, et al.. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118: 597.
12. Ikeuchi H, Kuroiwa T, Hiramatsu N, et al.. Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037.
13. Wolk K, Witte E, Hoffmann U, et al.. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn's disease. J Immunol 2007; 178: 5973.
14. Aujla SJ, Chan YR, Zheng M, et al.. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14: 275.
15. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al.. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947.
16. Radaeva S, Sun R, Pan HN, et al.. Interleukin-22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004; 39: 1332.
17. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al.. IL-22 but not IL-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27: 647.
18. Zhai Y, Qiao B, Gao F, et al.. Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology 2008; 47: 199.
19. Wolk K, Sabat R. Interleukin 22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006; 17: 367.
20. Park O, Wang H, Weng H, et al.. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011; 54: 252.
21. Wolk K, Kunz S, Witte E, et al.. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241.
22. Yang L, Zhang Y, Wang L, et al.. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol 2010; 53: 339.
23. Ki SH, Park O, Zheng M, et al.. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: Role of signal transducer and activator of transcription 3. Hepatology 2010; 52: 1291.
24. Sugimoto K, Ogawa A, Mizoguchi E, et al.. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534.
25. Brand S, Beigel F, Olszak T, et al.. IL-22 is increased in active Crohn's disease and promotes pro-inflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 290: G827.
26. Tohyama M, Hanakawa Y, Shirakata Y, et al.. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009; 39: 2779.
27. Cherian MG, Kang YJ. Metallothionein and liver cell regeneration. Exp Biol Med 2006; 231: 138.
28. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, et al.. Neutrophil accumulation as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation 1993; 55: 1265.
Keywords:

IL-22; Liver transplantation; Ischemia-reperfusion injury; Inflammation.

© 2012 Lippincott Williams & Wilkins, Inc.